Dr. O'Hara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Philadelphia, PA 19104Phone+1 215-360-0735
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2008 - 2012
Stony Brook University Health Sciences Center School of MedicineClass of 2008
Certifications & Licensure
PA State Medical License 2008 - 2024
Clinical Trials
- Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Start of enrollment: 2016 Jan 26
- A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Start of enrollment: 2016 Sep 01
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Start of enrollment: 2019 Nov 06
- Join now to see all
Publications & Presentations
PubMed
- 169 citationsAn NK-like CAR T cell transition in CAR T cell dysfunction.Charly R. Good, M. Angela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal
Cell. 2021-12-02 - 198 citationsEffect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.Thomas B. Karasic, Mark H. O'Hara, Arturo Loaiza-Bonilla, Kim A. Reiss, Ursina R. Teitelbaum
JAMA Oncology. 2019-07-01 - 47 citationsBiochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman
Nature Communications. 2021-07-16
Press Mentions
Verismo Therapeutics Announces the Activation of Its STAR-101 Clinical Trial at the University of PennsylvaniaMay 2nd, 2023- New Approach for Cell Therapy Shows Potential Against Solid Tumors with KRAS MutationsJuly 27th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
